Strong CDC and WHO surveillance data through mid-August 2026 show SARS-CoV-2 continuing to circulate at very low levels, with emergency department visits for COVID-19 at just 0.3% nationally despite a typical summer uptick and Rt estimates around 1.08 in growing states. Circulating Omicron descendants such as BA.3.2, NB.1.8.1, and XFG lineages exhibit immune-evasion mutations but remain below variant-of-concern thresholds, produce mild illness patterns consistent with prior seasonal waves, and have not triggered increased hospitalizations or deaths. This established endemic equilibrium, backed by real-time genomic and wastewater monitoring, underpins the market’s 96% implied probability of “No” new coronavirus pandemic in 2026. A realistic shift would require a novel, highly virulent spillover or rapid dominance by a strain combining substantial transmissibility gains with elevated severity—developments not yet observed in official tracking.